Drug Discovery World

AUGUST 7, 2023

The collaboration will work on developing exosome-encapsulated AAV (exoAAV) vectors as a novel gene delivery technology aimed at improving treatments for heart disease. Susmita Sahoo, Associate Professor of Medicine, Cardiology at Icahn Mount Sinai has been exploring the use of exosomes in gene therapy for several years.

Gene Therapy 52

Gene Therapy Gene Research In-Vivo 52

Pharmaceutical Technology

SEPTEMBER 21, 2022

Renovacor focuses on offering precision treatments for genetic cardiovascular and mechanistically-related ailments. The most advanced programme of the company is adeno-associated virus (AAV)-based gene therapy, REN-001. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Gene Therapy 147

Gene Therapy Gene Cardiology Genetics 147

STAT News

JULY 12, 2022

Somewhere in New Zealand, the first patient ever has been dosed with a kind of gene-editing treatment known as a base editor, a newer way of utilizing CRISPR for gene editing. The company studying the treatment, Verve Therapeutics, announced the news Tuesday. Continue to STAT+ to read the full story…

Gene Editing 98

Gene Editing Gene Therapy Gene Cardiology 98

Scienmag

MAY 17, 2021

Patients’ genetic profile strongly influences size of effect in early-phase trial People with extremely high levels of triglycerides (a type of fat in the blood) and a specific genetic profile saw a substantial reduction in triglycerides after taking the human monoclonal antibody evinacumab compared with those taking a placebo, in a study presented (..)

Genetics 42

Genetics Antibody Trials Gene Therapy 42

The Pharma Data

SEPTEMBER 15, 2020

Pfizer’s Rare Disease late-stage pipeline currently includes three gene therapy programs that, if successful, are expected to gain regulatory approval by the end of 2023, with an additional pipeline of 10 preclinical initiatives that are at various stages of maturity. and -50.4%

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52